istock-518308224_leventince
leventince / iStockphoto.com
4 July 2018Americas

LSIPR 50 2018: It’s not like selling cars

Managing and licensing the IP portfolio of a biomedical research centre as prestigious as the Broad Institute of MIT and Harvard may come with any number of challenges, but for Issi Rozen there is one key question he tackles in his day-to-day work as chief business officer: how can the Broad’s proprietary technology have the maximum impact possible, in a responsible way?

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
10 July 2026   Harbour’s trial counsel shares the strategy behind the company’s $20m win, revealing how a highly technical patent dispute became a case about credibility as much as science.
Americas
9 July 2026   Separate lawsuits target Indian and Taiwanese pharma companies as Exelixis seeks to keep rival cabozantinib products off the US market until key patents expire.
Americas
2 July 2026   A federal court has ruled in a dispute between a clinical trial technology company and a psychedelic drug developer over allegations of trade secret misuse during a bidding process.